PARP Inhibitor Development for Ovarian Cancer

PARP inhibitors (poly (ADP-ribose) polymerase inhibitors) are a class of cancer drugs that impede cellular repair mechanisms by inhibiting PARP enzymes, demonstrating particular efficacy in treating ovarian cancer. Alfa Cytology is dedicated to advancing the research of PARP inhibitors and offering comprehensive support and services for ovarian cancer-related research.

Introduction to PARP

PARP enzymes play a crucial role in detecting and repairing single-strand DNA breaks. Inhibiting PARP activity leads to the accumulation of these breaks, ultimately resulting in double-strand breaks. Normal cells have the ability to repair these breaks via homologous recombination (HR), utilizing proteins like BRCA1 and BRCA2. However, cancer cells with deficient HR-due to BRCA1 or BRCA2 mutations-cannot effectively repair double-strand breaks. This inability leads to genomic instability and eventually cell death, a phenomenon known as "synthetic lethality".

Fig 1. DNA repair and the effects of PARP inhibitor. (LUO L, et al., 2022)

Pipeline of PARP Inhibitors for Ovarian Cancer

Currently, several PARP inhibitors are available for the effective treatment of ovarian cancer, each demonstrating unique effects and application strategies tailored to individual needs. These drugs are utilized in various stages of therapy, ranging from the initial treatment phase to maintenance therapy.

Our Services

With its exceptional team of experts, Alfa Cytology is dedicated to advancing the development of PARP inhibitor, striving to improve the effectiveness of ovarian cancer therapeutic. Through continuous innovation, the company consistently pioneers new approaches in drug development, aiming to offer more effective therapies and achieve better therapeutic outcomes.

DNA-Dependent PARPs

• PARP1
• PARP2
• PARP3

End-anchor Polymerases (Tankyrases)

• PARP5a
• PARP5b

CCCH-type Zinc Finger PARPs

• PARP7
• PARP12
• PARP13

Macro PARPs

• PARP9
• PARP14
• PARP15

Workflow of PARP Inhibitor Development

Target Identification and Validation

Identify key molecular targets or factors involved in ovarian cancer growth by thoroughly studying the complex web of associated signaling pathways. This comprehensive analytical approach includes pinpointing critical molecules that particularly susceptible to targeted and effective therapeutic inhibition.

High-Throughput Screening (HTS)

Utilize advanced automated screening techniques to efficiently and systematically screen a vast library of diverse chemical compounds to identify promising potential drug candidates effective at inhibiting the specifically identified growth factors in cancer research studies.

Drug Optimization

Refine the chemical structure of identified drug candidates to enhance their therapeutic efficacy and minimize potential side effects, meticulously utilizing data and insights gathered from comprehensive preliminary study results and advanced computational modeling techniques.

Preclinical Research

Conduct comprehensive and thorough preclinical studies on the absorption, distribution, metabolism, and excretion (ADME) characteristics of the candidate drugs, alongside a detailed analysis of their specific molecular and cellular effects on ovarian cancer growth, signaling pathways, and overall disease progression.

Focused on the innovative therapeutic application of PARP inhibitors for ovarian cancer, Alfa Cytology employs state-of-the-art instrumentation and an expert technical team. If you have any questions or need more information about our PARP inhibitor services, please feel free to contact us. We look forward to your inquiry!

! For research use only.